NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell, essential for energy metabolism, DNA repair, and the activity of sirtuins (the longevity-associated deacetylase enzymes popularized by David Sinclair's research). Its age-related decline is one of the most studied hallmarks of aging — it declines across multiple tissues in parallel with reduced mitochondrial efficiency, accumulated DNA damage, and increased senescent cell burden. Whether supplementing NAD+ precursors can meaningfully reverse this decline in humans is the central question, and the answer is more nuanced than the supplement marketing suggests.
Two precursors dominate the market: NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide). Both enter the NAD+ biosynthesis pathway but at different steps. Both have human RCT data. Neither has proven longevity effects in humans — but both raise blood NAD+ levels, which is the proximate outcome most trials measure.
NAD+ is synthesized from multiple precursors via three main pathways. The Preiss-Handler pathway uses niacin (vitamin B3) → NaMN → NaAD → NAD+. The de novo synthesis pathway produces NAD+ from tryptophan via the kynurenine pathway (inefficient; only ~1% conversion). The salvage pathway — the one most relevant to supplementation — recycles nicotinamide (NAM) → NMN → NAD+ via the enzyme NAMPT (rate-limiting) or converts NR → NMN → NAD+. Both NR and NMN enter via this salvage pathway: NR is converted to NMN by NRK1/2 kinases; NMN is directly converted to NAD+ by NMNAT enzymes.
The key question: is the salvage pathway rate-limited by substrate (NMN/NR) or by the NAMPT enzyme? If NAMPT is the rate-limiting step, adding more substrate (taking NMN or NR supplements) won't increase NAD+ because the enzyme is already saturated. If substrate is rate-limiting, supplementation should work. The evidence suggests the answer depends on tissue type and age — in older adults with declining NAMPT activity, adding substrate appears to provide a meaningful boost.
Washington University 2023 (N=65, men 65+, 1,000mg/day × 10 weeks): Blood NAD+ increased significantly vs. placebo. Physical performance (6-minute walk test) did not significantly improve. Muscle strength improved marginally. No significant adverse events. Conclusion: NMN raises NAD+ in older men but the functional benefits at 10 weeks were limited.
Tokyo 2022 safety trial (N=10, 250mg × 4 weeks): NMN was safe and well-tolerated; NAD+ metabolite levels in blood increased dose-dependently. The smaller scale limits conclusions but supports safety profile.
Muscle study 2021 (N=25, amateur runners, 1,000mg/day × 6 weeks): Significant improvement in aerobic capacity (oxygen utilization efficiency) compared to placebo. NAD+ in peripheral blood mononuclear cells increased. This is one of the most promising functional outcome trials for NMN.
Chromadex-sponsored trials (2016–2022): Multiple trials (N=12–60, varying doses 250–2,000mg/day) consistently showed NR raises blood NAD+ levels dose-dependently. The 300mg dose roughly doubled blood NAD+ in the foundational 2016 Cell Metabolism paper (Trammell et al., N=12). These early trials established the basic pharmacokinetics.
Heart failure trial 2020 (JACC, N=30, 1,000mg NR × 12 weeks): Significant increase in blood NAD+ and its metabolites. No significant improvement in cardiac function endpoints. LVEF and exercise capacity unchanged. NR reached the circulation but cardiac benefit wasn't demonstrated.
Metabolic syndrome 2022 (N=30, 2,000mg/day × 12 weeks): Blood NAD+ increased 2.3-fold. Significant improvement in insulin sensitivity vs. placebo. Modest reduction in liver fat. One of the most compelling functional outcome trials for NR.
| Factor | NMN | NR |
|---|---|---|
| Molecular size | Larger (MW 334); cannot cross cell membrane directly — must be dephosphorylated to NR extracellularly first, OR enter via Slc12a8 transporter (present in gut, some tissues) | Smaller (MW 255); enters cells via nucleoside transporters (ENT1/2) directly |
| Blood NAD+ effect | Strong · confirmed in ≥3 RCTs | Very strong · more total trials; more consistent |
| Tissue penetration | May have advantage in specific tissues (gut, muscle) via Slc12a8; debated | Well-established broad tissue distribution |
| Human trial count | ~6–8 published RCTs | ~12–15 published RCTs |
| Functional outcome data | Some promising aerobic capacity data (2021 runners trial) | Better metabolic and insulin sensitivity data |
| Cost per effective dose | Higher (500–1,000mg doses common) | Lower (250–500mg doses more studied) |
| Safety profile | No serious adverse events in trials to date | No serious adverse events in trials to date |
| Regulatory status (US) | Currently legal dietary supplement; FDA reversal of 2023 IND designation | Cleaner regulatory history; never contested |
Bottom line: NR has more total human evidence and a cleaner regulatory history. NMN may have tissue-specific advantages not yet fully characterized. No head-to-head human trial comparing the two directly has been published as of mid-2026. For most users, NR is the more evidence-backed default; NMN is reasonable given emerging data and may be preferred by those who want the Sinclair-popularized formulation. Combining both at lower doses is practiced by some but lacks specific trial support.
NR dose: 250–500mg/day. Most human trials used 300–500mg. Higher doses (1,000–2,000mg) were used in some trials with good safety; not clearly more effective for blood NAD+ per the dose-response curve.
NMN dose: 500–1,000mg/day. Most published trials used 500mg or 1,000mg. Sublingual NMN has been proposed to improve absorption by bypassing gut conversion, but the pharmacokinetic advantage of sublingual vs. oral is debated.
Timing: Morning, with or without food. NAD+ is involved in circadian entrainment — morning dosing may align with natural NAD+ oscillation patterns.
Stack considerations: Resveratrol is often co-supplemented with NMN (per Sinclair's personal protocol) as a SIRT1 activator; the combined human evidence is thin but theoretically additive. Quercetin (a senolytic) is another common stack. TMG (trimethylglycine, 500mg) is sometimes added to counter potential methyl donor depletion from increased NAM metabolism.
Lifestyle amplifiers: Exercise independently raises NAD+ via AMPK activation and increased NAMPT expression in muscle. The combination of NR/NMN supplementation + regular exercise is theoretically more effective than either alone. Fasting also raises NAD+ — the three interventions likely have additive effects.
As an Amazon Associate, StackProtocol earns from qualifying purchases made through links on this page. This does not affect the price you pay.